Get App Journal Flyer

Total Page：16

File Type：pdf, Size：1020Kb

an Open Access Journal by MDPI Academic Open Access Publishing since 1996 an Open Access Journal by MDPI Editor-in-Chief Message from the Editorial Board Prof. Dr. Claudio Bassetti You are invited to contribute a research article or a comprehensive review for consideration and publication in Clinical and Translational Neuroscience (ISSN 2514- 183X). Clinical and Translational Neuroscience is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, case reports, and short communications on clinical and translational neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published. We would be pleased to welcome you as one of our authors. Author Benefits Open Access Unlimited and free access for readers No Copyright Constraints Retain copyright of your work and free use of your article Thorough Peer-Review No Space Constraints, No Extra Space or Color Charges No restriction on the length of the papers, number of figures or colors Discounts on Article Processing Charges (APC) If you belong to an institute that participates with the MDPI Institutional Open Access Program (IOAP) Aims and Scope Clinical and Translational Neuroscience (CTN) is an international, peer-reviewed, open access journal. The journal focuses on translating or developing basic neuroscience research into novel clinical neuroscience applications and therapies. We encourage basic and clinical scientists to publish their results in such detail that they can readily be reproduced. There is no restriction on the length of papers. Clinical research Neurosurgery General neuroradiology Neurovasular diseases Neuropediatrics History of neuroscience Clinical neurophysiology Neuroepidemiology Neuroimmunology Neuropathies Neuroscience/Translational neurology Autonomic nervous system disorders Neurogenetics Editorial Office Neuro-oncology CTN Editorial Office Neurorehabilitation [email protected] MDPI, St. Alban-Anlage 66 Neurotraumatology 4052 Basel, Switzerland Tel: +41 61 683 77 34 Neurocritical care Fax: +41 61 302 89 18 Neurosonology www.mdpi.com mdpi.com/journal/ctn MDPI is a member of Follow Us facebook.com/MDPIOpenAccessPublishing twitter.com/MDPIOpenAccess linkedin.com/company/mdpi weibo.com/mdpicn Wechat: MDPI-China blog.mdpi.com www.mdpi.com mdpi.com/journal/ctn See www.mdpi.com for a full list of offices and contact information. MDPI is a company registered in Basel, Switzerland, No. CH-270.3.014.334-3, whose registered office is at St. Alban-Anlage 66, CH-4052 Basel, Switzerland. Basel, July 2021.

Copy Link

Recommended publications

Pain Improvement in Parkinson's Disease Patients Treated
Journal of Personalized Medicine Article Pain Improvement in Parkinson’s Disease Patients Treated with Saﬁnamide: Results from the SAFINONMOTOR Study Diego Santos García 1,* , Rosa Yáñez Baña 2, Carmen Labandeira Guerra 3, Maria Icíar Cimas Hernando 4, Iria Cabo López 5 , Jose Manuel Paz González 1, Maria Gema Alonso Losada 3, Maria José Gonzalez Palmás 5, Carlos Cores Bartolomé 1 and Cristina Martínez Miró 1 1 Department of Neurology, CHUAC, Complejo Hospitalario Universitario de A Coruña, 15006 A Coruña, Spain; [email protected] (J.M.P.G.); [email protected] (C.C.B.); [email protected] (C.M.M.) 2 Department of Neurology, CHUO, Complejo Hospitalario Universitario de Ourense, 32005 Ourense, Spain; [email protected] 3 Department of Neurology, CHUVI, Complejo Hospitalario Universitario de Vigo, 36213 Vigo, Spain; [email protected] (C.L.G.); [email protected] (M.G.A.L.) 4 Hospital de Povisa, 36211 Vigo, Spain; [email protected] 5 Department of Neurology, CHOP, Complejo Hospitalario Universitario de Pontevedra, 36002 Pontevedra, Spain; [email protected] (I.C.L.); [email protected] (M.J.G.P.) * Correspondence: [email protected]; Tel.: +34-646-173-341 Citation: Santos García, D.; Yáñez Abstract: Background and objective: Pain is a frequent and disabling symptom in Parkinson’s disease Baña, R.; Labandeira Guerra, C.; (PD) patients. Our aim was to analyze the effectiveness of saﬁnamide on pain in PD patients from Cimas Hernando, M.I.; Cabo López, the SAFINONMOTOR (an open-label study of the effectiveness of SAFInamide on NON-MOTOR I.; Paz González, J.M.; Alonso Losada, symptoms in Parkinson´s disease patients) study.
[Show full text]
Journal of Neuroimmunology
JOURNAL OF NEUROIMMUNOLOGY AUTHOR INFORMATION PACK TABLE OF CONTENTS XXX . • Description p.1 • Audience p.1 • Impact Factor p.1 • Abstracting and Indexing p.1 • Editorial Board p.2 • Guide for Authors p.3 ISSN: 0165-5728 DESCRIPTION . The Journal of Neuroimmunology affords a forum for the publication of works applying immunologic methodology to the furtherance of the neurological sciences. Studies on all branches of the neurosciences, particularly fundamental and applied neurobiology, neurology, neuropathology, neurochemistry, neurovirology, neuroendocrinology, neuromuscular research, neuropharmacology and psychology, which involve either immunologic methodology (e.g. immunocytochemistry) or fundamental immunology (e.g. antibody and lymphocyte assays), are considered for publication. Works pertaining to multiple sclerosis, AIDS, amyotrophic lateral sclerosis, Guillain Barré Syndrome, myasthenia gravis, and brain tumors form a major focus. The scope of the Journal is broad, covering both research and clinical problems of neuroscientific interest. A major aim of the Journal is to encourage the development of immunologic approaches to analyse in further depth the interactions and specific properties of nervous tissue elements during development and disease. AUDIENCE . Researchers in neurology, immunology, neuroscience, neuropathology, and experimental neurology IMPACT FACTOR . 2020: 3.478 © Clarivate Analytics Journal Citation Reports 2021 ABSTRACTING AND INDEXING . BIOSIS Citation Index Chemical Abstracts Current Contents - Life Sciences Embase PubMed/Medline Pascal Francis Reference Update Scopus AUTHOR INFORMATION PACK 23 Sep 2021 www.elsevier.com/locate/jneuroim 1 EDITORIAL BOARD . Editors-in-Chief Robyn Klein, Washington University in St Louis School of Medicine, Campus Box 8301660 S. Euclid Ave., MO 63110-1093, Saint Louis, Missouri, United States of America Laura Piccio, The University of Sydney Brain and Mind Centre, Camperdown, Australia Gregory Wu, Washington University in St Louis School of Medicine, Campus Box 8301660 S.
[Show full text]
2021 Psychiatry CC-MOC Content Specifications
CONTINUING CERTIFICATION/MOC EXAMINATION IN PSYCHIATRY The American Board of Psychiatry and Neurology, Inc. (ABPN) has issued new, two- dimensional content specifications for the psychiatry, neurology and child neurology continuing certification/MOC examinations. Questions for the 2021 psychiatry, neurology and child neurology continuing certification examinations will conform to these new content specifications. Within the two-dimensional format, one dimension is comprised of disorders and topics while the other is comprised of competencies and mechanisms that cut across the various disorders of the first dimension. By design, the two dimensions are interrelated and not independent of each other. All of the questions on the examination will fall into one of the disorders/topics and will be aligned with a competency/mechanism. For example, an item on substance use could focus on treatment, or it could focus on systems-based practice. The psychiatry, neurology and child neurology continuing certification content specifications can be accessed from the Specialty MOC Exams section of our website. Candidates should use the new detailed content specifications as a guide to prepare for a continuing certification examination. Scores for these examinations will be reported in a standardized format rather than the previous percent correct format. In addition to these three continuing certification examinations, ABPN examinations will gradually conform to the new two-dimensional content specification starting in 2018. The American Board of Psychiatry and Neurology, Inc. is a not-for-profit corporation dedicated to serving the public interest and the professions of psychiatry and neurology by promoting excellence in practice through certification and continuing certification processes. For more information, please contact us at [email protected] or visit our website at www.abpn.com .
[Show full text]
The Vagus Nerve Can Predict and Possibly Modulate Non- Communicable Chronic Diseases: Introducing a Neuroimmunological Paradigm to Public Health
12/17/19, 08:13 Page 1 of 15 J Clin Med. 2018 Oct; 7(10): 371. PMCID: PMC6210465 Published online 2018 Oct 19. doi: 10.3390/jcm7100371 PMID: 30347734 The Vagus Nerve Can Predict and Possibly Modulate Non- Communicable Chronic Diseases: Introducing a Neuroimmunological Paradigm to Public Health Yori Gidron,1,* Reginald Deschepper,2 Marijke De Couck,2,3 Julian F. Thayer,4 and Brigitte Velkeniers5 1SCALAB UMR CNRS 9193, Université Lille, BP 60149, Villeneuve d’Ascq CEDEX 59653, France 2Mental Health and Wellbeing Research Group, Vrije Universiteit Brussel (VUB), Laerbeeklaan 103, 1090 Jette, Brussels, Belgium; [email protected] (R.D.); [email protected] (M.D.C.) 3Faculty of Health Care, University College Odisee, 9302 Aalst, Belgium 4Department of Neuroscience and Psychology, College of Medicine, Ohio State University, 33 Psychology Building, 1835 Neil Ave. Columbus, OH 43210, USA; [email protected] 5Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), Laerbeeklaan 103, 1090 Jette, Brussels, Belgium; [email protected] *Correspondence: [email protected]; Tel.: +32-498-56-82-77 Received 2018 Sep 19; Accepted 2018 Oct 15. Copyright © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Global burden of diseases (GBD) includes non-communicable conditions such as cardiovascular diseases, cancer and chronic obstructive pulmonary disease. These share important behavioral risk factors (e.g., smoking, diet) and pathophysiological contributing factors (oxidative stress, inflammation and excessive sympathetic activity).
[Show full text]
Taste and Smell Disorders in Clinical Neurology
TASTE AND SMELL DISORDERS IN CLINICAL NEUROLOGY OUTLINE A. Anatomy and Physiology of the Taste and Smell System B. Quantifying Chemosensory Disturbances C. Common Neurological and Medical Disorders causing Primary Smell Impairment with Secondary Loss of Food Flavors a. Post Traumatic Anosmia b. Medications (prescribed & over the counter) c. Alcohol Abuse d. Neurodegenerative Disorders e. Multiple Sclerosis f. Migraine g. Chronic Medical Disorders (liver and kidney disease, thyroid deficiency, Diabetes). D. Common Neurological and Medical Disorders Causing a Primary Taste disorder with usually Normal Olfactory Function. a. Medications (prescribed and over the counter), b. Toxins (smoking and Radiation Treatments) c. Chronic medical Disorders ( Liver and Kidney Disease, Hypothyroidism, GERD, Diabetes,) d. Neurological Disorders( Bell’s Palsy, Stroke, MS,) e. Intubation during an emergency or for general anesthesia. E. Abnormal Smells and Tastes (Dysosmia and Dysgeusia): Diagnosis and Treatment F. Morbidity of Smell and Taste Impairment. G. Treatment of Smell and Taste Impairment (Education, Counseling ,Changes in Food Preparation) H. Role of Smell Testing in the Diagnosis of Neurodegenerative Disorders 1 BACKGROUND Disorders of taste and smell play a very important role in many neurological conditions such as; head trauma, facial and trigeminal nerve impairment, and many neurodegenerative disorders such as Alzheimer’s, Parkinson Disorders, Lewy Body Disease and Frontal Temporal Dementia. Impaired smell and taste impairs quality of life such as loss of food enjoyment, weight loss or weight gain, decreased appetite and safety concerns such as inability to smell smoke, gas, spoiled food and one’s body odor. Dysosmia and Dysgeusia are very unpleasant disorders that often accompany smell and taste impairments.
[Show full text]
Additional Antidepressant Pharmacotherapies According to A
orders & is T D h e n r Werner and Coveñas, Brain Disord Ther 2016, 5:1 i a a p r y B Brain Disorders & Therapy DOI: 10.4172/2168-975X.1000203 ISSN: 2168-975X Review Article Open Access Additional Antidepressant Pharmacotherapies According to a Neural Network Felix-Martin Werner1, 2* and Rafael Coveñas2 1Higher Vocational School of Elderly Care and Occupational Therapy, Euro Academy, Pößneck, Germany 2Laboratory of Neuroanatomy of the Peptidergic Systems, Institute of Neurosciences of Castilla y León (INCYL), University of Salamanca, Salamanca, Spain Abstract Major depression, a frequent psychiatric disease, is associated with neurotransmitter alterations in the midbrain, hypothalamus and hippocampus. Deficiency of postsynaptic excitatory neurotransmitters such as dopamine, noradrenaline and serotonin and a surplus of presynaptic inhibitory neurotransmitters such as GABA and glutamate (mainly a postsynaptic excitatory and partly a presynaptic inhibitory neurotransmitter), can be found in the involved brain regions. However, neuropeptide alterations (galanin, neuropeptide Y, substance P) also play an important role in its pathogenesis. A neural network is described, including the alterations of neuroactive substances at specific subreceptors. Currently, major depression is treated with monoamine reuptake inhibitors. An additional therapeutic option could be the administration of antagonists of presynaptic inhibitory neurotransmitters or the administration of agonists/antagonists of neuropeptides. Keywords: Acetylcholine; Bupropion; Dopamine; GABA; Galanin; in major depression and to point out the coherence between single Glutamate; Hippocampus; Hhypothalamus; Major depression; neuroactive substances and their corresponding subreceptors. A Midbrain; Neural network; Neuropeptide Y; Noradrenaline; Serotonin; question should be answered, whether a multimodal pharmacotherapy Substance P with an agonistic or antagonistic effect at several subreceptors is higher than the current conventional antidepressant treatment.
[Show full text]
Interface of Epilepsy and Sleep Disorders
Seizure 1999; 8: 97 –102 View metadata, citation and similar papers at core.ac.uk brought to you by CORE Article No. seiz.1998.0257, available online at http://www.idealibrary.com on provided by Elsevier - Publisher Connector Interface of epilepsy and sleep disorders Roy G. Beran, Menai J. Plunkett & Gerard J. Holland St Lukes Hospital Telemetry and Sleep Centre, St Lukes Hospital, 18 Roslyn Street, Potts Point, NSW 2011, Australia Correspondence to: Dr Roy G. Beran, Suite 5, 6th Floor, 12 Thomas Street, Chatswood, NSW 2067, Australia Obstructive sleep apnoea was first brought to prominence by Henri Gastaut, a French epileptologist. Since that time the interface between epilepsy and sleep disorders has received less attention than might be justified, recognizing that sleep deprivation is a poignant provocateur for seizures. Sleep deprivation is often used as a diagnostic procedure during electroencephalography (EEG) when waking EEG has failed to demonstrate abnormality. Patients referred to an outpatient neurological clinic for evaluation of possible seizures in whom sleep disorder was suspected, either due to snoring during the EEG or based on history, were evaluated with all-night diagnostic polysomnography (PSG) and appropriate intervention administered as indicated. Patient and seizure demography, sleep disorder and response to therapy were reviewed and the interface explored. Fifty patients aged between 10 and 83 years underwent PSG. Approximately half were diagnosed with epilepsy and almost three-quarters had sleep disorders sufficiently intrusive to require therapy (either continuous positive air pressure (CPAP) or medication). With co-existence of epilepsy and sleep disorders, proper management of sleep disorders provided significant benefit for seizure control.
[Show full text]
Effect of Nutrition on Neurodegenerative Diseases. a Systematic Review
Nutritional Neuroscience An International Journal on Nutrition, Diet and Nervous System ISSN: 1028-415X (Print) 1476-8305 (Online) Journal homepage: https://www.tandfonline.com/loi/ynns20 Effect of nutrition on neurodegenerative diseases. A systematic review Vittorio Emanuele Bianchi, Pomares Fredy Herrera & Rizzi Laura To cite this article: Vittorio Emanuele Bianchi, Pomares Fredy Herrera & Rizzi Laura (2019): Effect of nutrition on neurodegenerative diseases. A systematic review, Nutritional Neuroscience, DOI: 10.1080/1028415X.2019.1681088 To link to this article: https://doi.org/10.1080/1028415X.2019.1681088 Published online: 04 Nov 2019. Submit your article to this journal Article views: 23 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=ynns20 NUTRITIONAL NEUROSCIENCE https://doi.org/10.1080/1028415X.2019.1681088 REVIEW Eﬀect of nutrition on neurodegenerative diseases. A systematic review Vittorio Emanuele Bianchi a, Pomares Fredy Herrerab and Rizzi Laurac aEndocrinology and Metabolism, Clinical Center Stella Maris Falciano, Falciano, San Marino; bDirector del Centro de Telemedicina, Grupo de investigación en Atención Primaria en salud/Telesalud, Doctorado en Medicina /Neurociencias, University of Cartagena, Colombia; cMolecular Biology, School of Medicine and Surgery, University of Milano-Bicocca, Monza Brianza, Italy ABSTRACT KEYWORDS Neurodegenerative diseases are characterized by the progressive functional loss
[Show full text]
Spinal Cord in Motor Neuron Diseases Using a Multi-Parametric MRI Approach
Université Pierre et Marie Curie Cerveau Cognition Comportement Laboratoire d’Imagerie Biomédicale / Systèmes Dynamiques Anatomo-Fonctionnels chez l’Homme Thèse de Doctorat en Neurosciences Présentée par Mohamed-Mounir EL MENDILI Analysis of the structural integrity of the spinal cord in motor neuron diseases using a multi-parametric MRI approach Dirigée par Véronique MARCHAND-PAUVERT et Pierre-François PRADAT Présentée et soutenue le 13 Décembre 2016 devant le jury composé de Devant un jury composé de : M. Peter BEDE (PU-PH) Trinity College Dublin, Irland Rapporteur Mme. Virginie CALLOT (DR) Aix-Marseille Université Rapporteur M. Philippe CORCIA (PU-PH) Université François-Rabelais, Tours Examinateur M. Stéphane LEHERICY (PU-PH) Université Paris VI Examinateur Mme. Véronique MARCHAND-PAUVERT (DR) Université Paris VI Directeur de thèse M. Pierre-Francois PRADAT (PH) Université Paris VI Co-directeur de thèse This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. À tous les patients atteints d’une des maladies du motoneurone Contents Contents ..................................................................................................................................... i Remerciements .................................................................................................................... iii List of Tables .......................................................................................................................... iv List of Figures ........................................................................................................................
[Show full text]
A Systematic Review of Nutritional Risk Factors of Parkinson's Disease
Nutrition Research Reviews (2005), 18, 259–282 DOI: 10.1079/NRR2005108 q The Authors 2005 A systematic review of nutritional risk factors of Parkinson’s disease Lianna Ishihara* and Carol Brayne Department of Public Health and Primary Care, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 2SR, UK A wide variety of nutritional exposures have been proposed as possible risk factors for Parkinson’s disease (PD) with plausible biological hypotheses. Many studies have explored these hypotheses, but as yet no comprehensive systematic review of the literature has been available. MEDLINE, EMBASE, and WEB OF SCIENCE databases were searched for existing systematic reviews or meta-analyses of nutrition and PD, and one meta-analysis of coffee drinking and one meta-analysis of antioxidants were identified. The databases were searched for primary research articles, and articles without robust methodology were excluded by specified criteria. Seven cohort studies and thirty-three case–control (CC) studies are included in the present systematic review. The majority of studies did not find significant associations between nutritional factors and PD. Coffee drinking and alcohol intake were the only exposures with a relatively large number of studies, and meta-analyses of each supported inverse associations with PD. Factors that were reported by at least one CC study to have significantly increased consumption among cases compared with controls were: vegetables, lutein, xanthophylls, xanthins, carbohydrates, monosaccharides, junk food, refined sugar, lactose, animal fat, total fat, nuts and seeds, tea, Fe, and total energy. Factors consumed significantly less often among cases were: fish, egg, potatoes, bread, alcohol, coffee, tea, niacin, pantothenic acid, folate and pyridoxine.
[Show full text]
Neuroscience: the Science of the Brain
NEUROSCIENCE SCIENCE OF THE BRAIN AN INTRODUCTION FOR YOUNG STUDENTS British Neuroscience Association European Dana Alliance for the Brain Neuroscience: the Science of the Brain 1 The Nervous System P2 2 Neurons and the Action Potential P4 3 Chemical Messengers P7 4 Drugs and the Brain P9 5 Touch and Pain P11 6 Vision P14 Inside our heads, weighing about 1.5 kg, is an astonishing living organ consisting of 7 Movement P19 billions of tiny cells. It enables us to sense the world around us, to think and to talk. The human brain is the most complex organ of the body, and arguably the most 8 The Developing P22 complex thing on earth. This booklet is an introduction for young students. Nervous System In this booklet, we describe what we know about how the brain works and how much 9 Dyslexia P25 there still is to learn. Its study involves scientists and medical doctors from many disciplines, ranging from molecular biology through to experimental psychology, as well as the disciplines of anatomy, physiology and pharmacology. Their shared 10 Plasticity P27 interest has led to a new discipline called neuroscience - the science of the brain. 11 Learning and Memory P30 The brain described in our booklet can do a lot but not everything. It has nerve cells - its building blocks - and these are connected together in networks. These 12 Stress P35 networks are in a constant state of electrical and chemical activity. The brain we describe can see and feel. It can sense pain and its chemical tricks help control the uncomfortable effects of pain.
[Show full text]
Neuroimmunology: the Brain As a Cognitive Antigen
Neuroimmunology: The brain as a cognitive antigen Prof Anat Achiron, MD, PhD Director, Multiple Sclerosis Center & Neurogenomic Laboratory Sheba Medical Center, Tel-Hashomer ISRAEL Itinerary • Self-recognition • Basic brain immunology • The brain as an antigen • BBB • PML • Myelin • Autoimmunity • Multiple sclerosis • Brain plasticity • The brain as a cognitive antigen Multiple Sclerosis Center Sheba Multiple Sclerosis Center Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, ISRAEL 1995 – 2016…. No of MS patients = 4071 http://research.sheba.co.il/e/13/ SheBa Comprehensive Multiple Sclerosis Center Nursing Physiotherapy Neurology Sport, Gait, Balance Hydrotherapy Neuro- Occupational Ophthalmology therapy Patient Speech Orthopedics therapy Expert MS Center Neuro-urology Social work Sexual counseling Creative art Psychiatry Psychology Family Group therapy counseling Sheba Comprehensive Multiple Sclerosis Center Epidemiology Image Analysis Cognition Multiple Sclerosis Neuroimmunology Center Gene expression Education Rehabilitation Clinical trials Immune system– Basic definitions n Innate immune system aimed at acute rapid immune response. n Detects pathogens or PAMPs (pathogen-associated molecular patterns) which are characteristic structures present in microorganisms by receptors belonging to two diverse receptor families: the Toll-like receptor family and the Nod protein (or NBD-LRR protein) family. n In vertebrates, the innate immune system activates the more evolved adaptive immune system, which is composed of T and B lymphocytes. Immune system – detection & response Innate immune response: 1) Antigen-presenting cells (APCs) are activated through recognition of pathogens (or PAMPs) by receptors such as TLRs or NBD-LRR proteins. 2) This activation leads to the production of inflammatory cytokines and the expression of co-stimulatory molecules on the cell surface. Adaptive immune response: 3) Antigens will be presented by MHC molecules on APCs to T lymphocytes (Signal 1).
[Show full text]